Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

Fig. 2

Panel a displays: 50%, 75%, 100% MMDs RR after 1, 3 and 6 months of therapy in HFEM patients (on the left) and 50%, 75%, 100% MHDs RR after 1, 3 and 6 months of therapy in CM patients (on the right). Panel b graphically shows the percentage of HFEM patients achieving at least 3, 4, 5 or 6 cumulative months with 50% MMDs RR (on the left) and the percentage of CM patients achieving at least 3, 4, 5 or 6 cumulative months with 50% MHDs RR (on the right)

Back to article page